US 12,227,768 B2
Methods and products for transfection
Matthew Angel, Cambridge, MA (US); and Christopher Rohde, Cambridge, MA (US)
Assigned to Factor Bioscience Inc., Cambridge, MA (US)
Filed by Factor Bioscience Inc., Cambridge, MA (US)
Filed on Oct. 3, 2022, as Appl. No. 17/958,816.
Application 17/958,816 is a continuation of application No. 16/562,497, filed on Sep. 6, 2019, granted, now 11,492,600.
Application 16/562,497 is a continuation of application No. 16/374,482, filed on Apr. 3, 2019, granted, now 10,443,045, issued on Oct. 15, 2019.
Application 16/374,482 is a continuation of application No. 16/037,597, filed on Jul. 17, 2018, granted, now 10,301,599, issued on May 28, 2019.
Application 16/037,597 is a continuation of application No. 15/947,741, filed on Apr. 6, 2018, granted, now 10,131,882, issued on Nov. 20, 2018.
Application 15/947,741 is a continuation of application No. 15/844,063, filed on Dec. 15, 2017, granted, now 9,969,983, issued on May 15, 2018.
Application 15/844,063 is a continuation of application No. 15/605,513, filed on May 25, 2017, granted, now 9,879,228, issued on Jan. 30, 2018.
Application 15/605,513 is a continuation of application No. 15/358,818, filed on Nov. 22, 2016, granted, now 9,695,401, issued on Jul. 4, 2017.
Application 15/358,818 is a continuation of application No. 15/178,190, filed on Jun. 9, 2016, granted, now 9,562,218, issued on Feb. 7, 2017.
Application 15/178,190 is a continuation of application No. 14/810,123, filed on Jul. 27, 2015, granted, now 9,399,761, issued on Jul. 26, 2016.
Application 14/810,123 is a continuation of application No. 13/931,251, filed on Jun. 28, 2013, granted, now 9,127,248, issued on Sep. 8, 2015.
Application 13/931,251 is a continuation of application No. 13/465,490, filed on May 7, 2012, granted, now 8,497,124, issued on Jul. 30, 2013.
Claims priority of provisional application 61/637,570, filed on Apr. 24, 2012.
Claims priority of provisional application 61/569,595, filed on Dec. 12, 2011.
Claims priority of provisional application 61/566,948, filed on Dec. 5, 2011.
Prior Publication US 2023/0151335 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/074 (2010.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01); C12N 5/0789 (2010.01); C12N 5/095 (2010.01); C12N 15/85 (2006.01); C12N 5/00 (2006.01)
CPC C12N 5/0696 (2013.01) [C12N 5/0625 (2013.01); C12N 5/0647 (2013.01); C12N 5/0656 (2013.01); C12N 5/0657 (2013.01); C12N 5/0676 (2013.01); C12N 5/0695 (2013.01); C12N 15/85 (2013.01); C12N 5/0018 (2013.01); C12N 2500/25 (2013.01); C12N 2500/33 (2013.01); C12N 2500/36 (2013.01); C12N 2500/84 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/608 (2013.01); C12N 2501/998 (2013.01); C12N 2506/09 (2013.01); C12N 2506/45 (2013.01)] 20 Claims
 
1. A method for reprogramming a differentiated cell to a less differentiated state, the method comprising:
(a) providing the differentiated cell;
(b) culturing the differentiated cell; and
(c) transfecting the differentiated cell with one or more synthetic RNA molecules,
wherein the one or more synthetic RNA molecules include at least one RNA molecule encoding one or more reprogramming factors comprising a DNA-binding protein; and
wherein the transfecting results in the cell expressing the one or more reprogramming factors to result in the cell being reprogrammed to the less differentiated state; and
wherein step (c) is performed not in the presence of irradiated fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the differentiated cell to the less differentiated state.